Although the pathways of cell growth and apoptosis have been extremely investigated, it seems still unclear how cell growth inhibition and apoptosis are controlled or switched over. Cancer cells enter the cell cycle by being stimulated by a growth factor, such as epidermal growth factor (EGF) and insulin-like growth factor (IGF). Recently, vascular endothelial growth factor (VEGF) known as an inducer of angiogenesis is focused on,because of its function as growth factor. In fact, all human lung cancer cell lines we maintain secrete VEGF,and VEGF is similarly suspected to function as a growth factor. On the other hand, anticancer chemotherapeutic agents induce cell growth inhibition or apoptosis. DNAdamaging anticancer agents stimulate wild type p53 production, and p53 has a key role in the control of G1/S check point and then decides the outcome of cells to apoptosis or cell growth inhibition. Thus, p53 is very important to assess the efficiency of chemotherapeutic agents. DNA damage reaches apoptosis through two pathways, mitochondrial pathway initiated by Bcl-2 family and death receptor pathway stimulated by TNFreceptor superfamily activation. However, we found that all human lung cancer cell lines we maintained expressed Fas, a member of TNF-receptor superfamily. Fas was localized in the cytoplasm in exponentially growing cells and in the membrane in confluent cells. Interestingly, Fas levels in confluent cells were significantly correlated with their doubling times (r = 0.757, p = 0.0088). Moreover, growth factor stimulation such as EGF, IGF, and VEGF induced Fas internalization. From these results we suppose that Fas may function as a cell growth inhibitor as well as a death receptor just like p53.
View full abstract